In a Securities and Exchange Commission (SEC) filing last Friday, US oncology focused biotech Syros Pharmaceuticals (Nasdaq: SYRS) disclosed it has received notice from Incyte Corp (Nasdaq: INCY) that it was opting out of a blood cancer treatment collaboration dated January 2018, on novel therapies for myeloproliferative neoplasms.
Syros’ shares closed up 1.6% at $3.82 following the announcement, which comes just a couple of weeks after US pharma giant Pfizer (NYSE: PFE) also terminated a deal with the company.
The termination of the Incyte accord will be effective within 60 days of August 9, 2023.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze